Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of Phase 3 data.

Raccontata daendpoints.news